KRYS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 5.25%, SMA50 15.42%, SMA200 43.56%). The stock’s 14-day RSI is 68.35 (firm momentum), while the ATR of 7.77 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -3.14% below its high and over 96.09% above its low. Average 10-day trading volume of 357.98 thousand shares is slightly above the 3-month average of 302.65 thousand, indicating heightened recent market interest.

Krystal Biotech, Inc. has 28.94 million shares outstanding. The public float is 22.98 million shares, elevated short interest at 19.67% of float. This equals 3.40 million shares. The short ratio is 11.72 days. Institutional investors hold 114.52% of the float. Insiders own 11.86%. Krishnan Krish S holds 1.41 million shares, Krishnan Suma has 1.41 million shares and JANNEY DANIEL has 107.36 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.26 thousand shares across 12 transactions.

Krystal Biotech, Inc. (NASDAQ:KRYS) closed at $240.80 USD, gaining $7.43 (3.18%) from the previous close of $233.37. The stock is currently within 5% of its 52-week high $122.80 and $248.59. With a market capitalization of about $6.98 billion, Krystal Biotech, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 310.01 thousand shares, trading with heavier-than-usual volume. Headquartered in Pittsburgh, PA, Krystal Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Krish S. Krishnan, the company employs approximately 275 people and listed since September 20, 2017. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.

Wall Street analysts project EPS growth of 49.8% annually over the next five years. The latest quarter delivered EPS of $2.66. The next quarter is forecast at $1.56. Next year's EPS is expected at $79.12. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 16 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $255.00 to $155.00. The high target offers 5.9% upside. The low target suggests -35.63% downside. The mean target is $215.50. This offers -10.51% upside. Krystal Biotech, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 03, 2025, missed forecasts by 137.5%. The prior quarter beat by 19.44%. Over the last six quarters, Apple has recorded several small beats. These include 5.0% in August 05, 2024.

Krystal Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $296.28. This means the shares are trading below this model’s fair value.

Krystal Biotech, Inc. trades at a P/E ratio of 35.05, slightly above the S&P 500 average, with a price-to-sales ratio of 18.71 and a price-to-book ratio of 6.13 trading at moderately above to book value. The P/FCF stands at 42.17, also above market averages.

Our AI price prediction model suggests that Krystal Biotech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.53%, with price expected at $261.34 by January 02, 2026, within a range of $255.95 to $266.39 3-Month Outlook: Projected rise of 1.8%, reaching $245.13 by March 19, 2026, with a range of $236.50 to $254.06. 1-Year Outlook: Projected gain of 13.43%, with price at $273.15 by December 18, 2026, within a range of $262.53 to $282.77.

Krystal Biotech, Inc. (NASDAQ:KRYS) shares are up 53.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Krystal Biotech, Inc. trading at a premium to the broader market with a P/E of 35.05. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $170.51, suggesting -29.19% downside. Our AI forecast model points to short-term strength (8.53% over two weeks), a medium-term rise (1.8% over three months), and a longer-term gain (13.43% over one year), with expected trading ranges indicating moderate volatility.